HLA-A2 Antibody (BB7.2): sc-32236

HLA-A2 Antibody (BB7.2) is a mouse monoclonal IgG2b kappa light chain antibody that detects the HLA-A2 protein of human origin by flow cytometry (FCM). Anti-HLA-A2 antibody (BB7.2) is available in both non-conjugated and various conjugated forms, including phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates, providing versatility for different experimental needs. Human leukocyte antigen A2 (HLA-A2) plays a crucial role as a class I histocompatibility molecule, integral to the immune response by presenting peptides on the cell surface to cytotoxic T lymphocytes (CTLs). This function is vital for the recognition and elimination of infected or malignant cells, making HLA-A2 a key player in immune surveillance. Notably, HLA-A2 is implicated in autoimmune thyroid dysfunction in patients undergoing interferon-alpha therapy for chronic hepatitis C, highlighting HLA-A2′s significance in both immune response and disease pathology. Furthermore, research has shown that HLA-A2 antigens are downregulated in response to HIV, particularly in primary T cells, which can lead to evasion of the immune response. Such downregulation is also observed in various cell lines, including β and astrocytoma cells, indicating a broader impact on immune evasion strategies. Modifications to the heavy chain of HLA-A2 can enhance the presentation of specific HIV-1 epitopes, thereby improving the recognition and lysis of infected cells by HLA-A2 restricted CD8+ CTLs. Anti-HLA-A2 antibody (BB7.2) serves as an essential tool for researchers studying the complexities of immune responses, particularly in the context of viral infections and autoimmune diseases.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

HLA-A2 Antibody (BB7.2) References:

1. HIV's evasion of the cellular immune response.  |  Collins, KL. and Baltimore, D. 1999. Immunol Rev. 168: 65-74. PMID: 10399065
2. [Autoimmune thyroid disease induced by interferon therapy].  |  Murakami, M., et al. 1999. Nihon Rinsho. 57: 1779-83. PMID: 10483250
3. Creating HIV-1 reverse transcriptase cytotoxic T lymphocyte target structures by HLA-A2 heavy chain modifications.  |  Dela Cruz, CS., et al. 2000. Int Immunol. 12: 1293-302. PMID: 10967024
4. [Human tumor-rejection antigens and peptides from genes to clinical research].  |  Itoh, K., et al. 2000. Nihon Geka Gakkai Zasshi. 101: 612-7. PMID: 11022676
5. A general strategy to enhance immunogenicity of low-affinity HLA-A2. 1-associated peptides: implication in the identification of cryptic tumor epitopes.  |  Tourdot, S., et al. 2000. Eur J Immunol. 30: 3411-21. PMID: 11093159
6. HLA-A2 Alleles Mediate Alzheimer's Disease by Altering Hippocampal Volume.  |  Wang, ZX., et al. 2017. Mol Neurobiol. 54: 2469-2476. PMID: 26979752
7. A chimeric HLA-A2:β2M:Ig fusion protein for the study of virus-specific CD8+ T-cells.  |  Ribeiro, ÁL., et al. 2021. J Immunol Methods. 492: 112997. PMID: 33600818
8. Identification of HLA-A2-Restricted Mutant Epitopes from Neoantigens of Esophageal Squamous Cell Carcinoma.  |  Wang, Z., et al. 2021. Vaccines (Basel). 9: PMID: 34696226
9. Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy.  |  Liu, X., et al. 2022. J Immunother Cancer. 10: PMID: 35338087
10. Anti-HLA-A2-CAR Tregs prolong vascularized mouse heterotopic heart allograft survival.  |  Wagner, JC., et al. 2022. Am J Transplant. 22: 2237-2245. PMID: 35434896
11. Unsupervised and supervised AI on molecular dynamics simulations reveals complex characteristics of HLA-A2-peptide immunogenicity.  |  Weber, JK., et al. 2023. Brief Bioinform. 25: PMID: 38233090
12. Development of therapeutic monoclonal antibodies against DKK1 peptide-HLA-A2 complex to treat human cancers.  |  Qian, J., et al. 2024. J Immunother Cancer. 12: PMID: 38267222

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-HLA-A2 Antibody (BB7.2) has 12 citations in a variety of scientific publications.

Primary antibodies like Anti-HLA-A2 Antibody (BB7.2) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

HLA-A2 Antibody (BB7.2) Specifications

Alternate Product Name: HLAA2

Product Clone Name: BB7.2

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG_2b kappa light chain

Amino Acids:

Epitope Target: HLA-A2

Epitope Species: human

Product Reactivity/Detection: epitope on α 2 domain of HLA-A2

Species Reactivity/Detection: human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: FCM

Vialing Information: Each vial contains 200 µg IgG_2b kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 12 citations in various scientific publications

Available Conjugates/Forms for HLA-A2 Antibody (BB7.2): AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, PE: Phycoerythrin